Ultrasound or FNA for Predicting Node Positive in Breast Cancer
|
|
- Emily Sanders
- 5 years ago
- Views:
Transcription
1 Ultrasound or FNA for Predicting Node Positive in Breast Cancer Chiun Sheng Huang, MD, PhD, MPH Professor and Chairman Department of Surgery Director of Breast Care Center National Taiwan University Hospital National Taiwan University College of Medicine 1
2 SLNB has replaced ALND for axillary staging for patient without clinically palpable node 2014 ASCO Guideline of SLNB Recommendation 1: Clinicians should not recommend ALND for women with early stage breast cancer who do not have positive sentinel nodes. 2
3 Before Z0011: Preoperative Ultrasound can Detect LN Metastasis and Save Patients from SLND van Rijk ASO 2006 Ultrasound suspicious 176 (24%) 732 axillae FNAC positive 59 (34%) FNAC negative 117 (66%) LN-positive 58 (98%) LN-negative 1 (2%) false+ SLN positive 36 (31%) SLN negative 81 (69%) Ultrasound not suspicious 556 (76%) SLN-positive 177 (32%) SLN-negative 379 (68%)
4 Comparison of diagnostic performance of US and US FNA in diagnosis of axillary lymph node metastasis US only (%) Adding US FNAB (%) p value Sensitivity 73/129 (56.3) 51/129 (39.5) < Specificity 205/253 (81.0) 242/253 (95.7) < Specificity a 205/243 (84.4) 242/243 (99.6) < PPV 73/121 (60.3) 51/62 (82.3) < PPV a 73/111 (65.8) 51/52(98.1) NPV 205/261 (78.5) 242/320 (75.6) a Excluding complete responders to chemotherapy ASO 2011: 741
5 US-guided Sampling of Axillary LNs in Breast Cancer Authors Number of axillae FNAC/ CNB Number (%) of axillae with positive LN Number (%) diagnosed preoperatively Sampling criteria Damera 166 CNB/FNA 64(39%) 27(42%) Suspicious node, FNA if core not feasible % of SLNB avoided 16% Abe et al CNB 80 (56%) 64 (64%) suspicious node, one 44% (47%) Single node dekanter 17% Et al. 2 FNAC 31 (17%) regardless of echo pattern,69 cases LN visible Deurloo et al FNAC 93 (35%) 37(31%) suspicious node, one 14% Van Riijk et al FNAC (21%) All suspicious nodes 8% Cilisson et al FNAC 93(48%) 52 (56%) All suspicious nodes 27% Damera Br J Cancer 2003, 1.Radiology 2009:41, 2. Br J Surg 1999:1459, 3. EuJ Cancer 2003:1068, 4. ASO 2006; 13;31, 5. Eu J Surg Oncol 2008:497
6 University Hospital of North Staffordshire, UK 52/142 (37%) cases were LN meta, 51(36%) had abnormal axilla ultrasound Ultrasound sensitivity for lobular ca. was 36% versus 76% for all other The most significant factor producing discordance between preoperative ultrasound and final LN meta was tumor type (p< ) The Breast Journal, Volume 19 Number 1,
7 cortex fatty hilum
8 US benign Thickened Cortex
9
10 Ultrasound Features of Axillary Nodes and Results of Ultrasound Guided Needle Localization Surgical Results, No. (%) of Cases Needle Localized Node to Node Based SLND/ALND Analysis Positive (n=41) Negative (n=150) Positive (n=54) Negative (n=137) Cortical thickness of 1.5 mm 1 (2) 42 (98) 3 (7) 40 (93) 1.5 < cortical thickness 2.5 mm 5 (6) 75 (94) 11 (14) 69 (86) 2.5 < cortical thickness 3.5 mm 19 (40) 29 (60) 23 (48) 25 (52) Cortical thickness of > 3.5 mm and intact fatty hilum Cortical thickness of > 3.5 mm and loss of fatty hilum 7 (70) 3 (30) 7 (70) 3 (30) 9 (90) 1 (10) 10 (100) 0 (0) Cho et. al. AJR 2009:1731
11 Correlations between Ultrasound and CNB Findings in 144 Patients Abe et al. Radiology 2009:41 CNB Finding* US Finding Malignant Benign Sensitivity Specificity PPV NPV Cortical thickening (63/80) 64 (41/64) 7(63/86) 71 (41/58) Absence of fatty hilum (26/80) 97 (62/64) 93(26/28) 53 (62/116) NHBF (52/80) 77 (49/64) 78 (52/67) 64 (49/77) Cortical thickening and NHBF combined (52/80) 81 (52/64) 81 (52/64) 65 (52/80) NHBF: Non-hilar blood flow * Data are numbers of lymph nodes (same as numbers of patients). Data are percentages, with the numbers of patients used to calculate the percentages in parentheses. NPV=negative predictive value, PPV=positive predictive value. P<0.001 for all correlations between US and histopathologic findings at X2 testing.
12 Ultrasound lymph node features of high risk for axillary metastases Br J Radiol Aug; 81(968): cortex thickness indicative of 1-3 N(+) absence of fatty hilum, abnormal lymph node shape and increased peripheral blood flow: indicative of >3 N+ US benign US suspicious US positive
13 2014 ASCO Guideline of SLNB Recommendation 2.1: Z0011 Clinicians should not recommend ALND for women with early breast cancer who have one or two sentinel lymph node metastases and will receive BCS with conventionally fractionated whole breast radiotherapy and systemic therapy 13
14 Can US/FNA positive patients undergo BCS and SLNB? Data are insufficient to address whether FNApositive patients can undergo SLNB (under the assumption that resected SLNs represent the FNAbiopsied node) and then avoid ALND after resection of the metastatic SLN. ASCO guideline: Clinicians may still perform SLNB if the abnormal lymph node is removed.
15 Institute of Oncology Ljubljana, Slovenia 658 patients s/p SLN Ultrasound ( ) Clinically ( ) SLN positive 40%(114/286), 32% if ITC excluded Non SLN positive 23% (18/79 ALND) 9.2% if all had ALND LN (+) no. (mean) 1.7 (median) 1 39% (144/372) 45% (43/96) Breast Cancer Res Treat Jun;97(3):293-9.
16 Positive Axillary Ultrasound does not exclude the chance of 1 or 2 positive sentinel nodes 1573 Patients of National Taiwan Uni. Hospital Ultrasound Number of Total Positive Lymph Nodes >3 Total Positive/ Suspicious Negative / Slightly suspicious % 39.7% 22.1% 100% % 20.7% 1.9% 100% Total Fisher's Exact Test: p <
17 2014 ASCO Guideline of SLNB Recommendation 2.2: Clinicians may offer ALND for women with early stage breast cancer with nodal metastases found on SNB who will receive mastectomy. IBCSG 23 01: No difference in 5 year DFS between SLNB alone vs. ALND if SLN had micrometastasis Omitting ALND in Mastectomy patients? (9% of patients in each arm)
18 AUS benign (n=1115) SLN detection failure(n=16) NTUH Patients receiving BCS (n=606) or Mastectomy (n=509) SLN( )(n=883) (80.3%) SLN detection success(n=1099 SLN micrometastasis (n=48) ) (100%) (4.4%) ALND not done (BCs 22, mastec. 8) ALND done Non SLN( )(n=14) 77.8% ALND done Non SLN(+)(n=4) 22.2% SLN macrometastasis (n=168) (15.3%) ALND not done(n=55) ALND done Non SLN( )(n=83) 73.5% ALND done Non SLN(+)(n=30) 26.5%
19 Ultrasound/FNA for Axillary Staging in Different Scenarios When mastectomy is planned- preoperative ultrasound can detect axillary LN metastasis and save patients from SLND When breast-preserving surgery is planned- if US LN(+) but LN not palpable, SLND is still feasible. However, if the US features favor more than 3 positive nodes, ALND can be considered. And when US LN(-), 19
20 When axillary ultrasound is negative. the chance of having negative sentinel node is about 77%, and the chance of having more than two or three positive nodes is low For people who still have doubt in Z0011, it is probably safe to follow Z0011 when US is negative. It is not necessary to do intraoperative examination of sentinel node for breast conserving surgery The chance of needing radiation therapy after mastectomy is low. Immediate reconstruction after mastectomy can be planned. 20
21 Ultrasound/FNA for Axillary Staging in Different Scenarios When mastectomy is planned- preoperative ultrasound can detect axillary LN metastasis and save patients from SLND When breast-preserving surgery is planned- SLND is still feasible if US LN(+) but LN not palpable. However, if the US characteristics favor more than 3 positive nodes, ALND can be considered. And when US LN(-) When neoadjuvant therapy is planned - 21
22 2014 ASCO Guideline of SLNB SLNB may be offered before or after neoadjuvant systemic therapy (NACT), but the procedure seems less accurate after NACT. Ultrasound is helpful in determining the sequence of SLNB and neoadjuvant chemotherapy (NAC) US LN( ): SLND before or after NAC US LN(+): NAC first, then surgery and SLNB/ALND 22
23 SLND before Neoadjuvant Chemotherapy If the information of lymph node status is needed before neoadjuvant chemotherapy (NAC) If SLN is negative, or even with two positive SLNs and breast-preserving surgery planned (as in Z0011 trial), before NAC, there is no need to repeat axillary staging after NAC While if SLN is positive before neoadjuvant (more than 2 SLNs in breast-preserving surgery), repeating SLNB after chemotherapy may not be reliable (SENTINA study: FNR 52%) and ALND should be considered after chemotherapy. (SLN will be positive in about 20-25% of patients who have negative axillary ultrasound) 23
24 SLND after Neoadjuvant Chemotherapy NC could convert 30 to 40 % of node(+) to node(-) SLND done after NC in patients with positive node at diagnosis may save patients from ALND It is good to know whether there is axillary pcr, as axillary pcr is associated with good prognosis (even more prognostic than tumor pcr or not, as demonstrated in a study of 403 patients with preoperative confirmed nodal metastasis. Hennessy JCO 2005:9304 ) Identification rate of SLN after NC is % 24
25 SLNB after Neoadjuvant Chemotherapy in Node-Positive Patients IDR False Negative Rate Tracer Tracer SLN number Post CT AUS 2 SLNs removed IHC Single Dual Single Dual 1 2 No Yes No Yes SENTINA 77.4% 87.8% 16.0% 8.6% 24.3% 9.6% (18% if 2SLNs) ACOSOG Z % 10.8% 31.5% 9.1% if 3 SLNs, 21.1% if2 SLNs 12.6 % (N1) 9.8% US(-) SNFNAC 16.0% 5.2% 18.2% 4.9% (with IHC) 13.3% 8.4% IDR: Identification Rate SENTINA Lancet oncology 14(7): SNFNAC JCO Jan 20;33(3): ACOSOG Z1071 (Alliance) JAMA Oct 9;310(14): , JCO 2015 doi: /JCO
26 FNR of SLNB after NAC in patients with positive nodes before NAC NTUH experience Variable Pre NAC LN metastasis No. of Patients No. False Negative FNR % SLN number % % < % Change of LN status after NAC positive negative % SLN total number % % < %
27 When Neoadjuvant Chemotherapy (NCT) planned AUS Negative Negative/Positive SLNB NCT (-) (+) AUS NCT NCT Negative Positive ALND (20-25%, Lower if BCS) SLNB with dual tracer ALND - if only one SLN is harvested (20-31% in 3 trials) or any SLN has isolated tumor cells, micrometastasis, macro-metastasis 27 ALND
28 Sentinel node vs Observation after axillary UltraSouND (SOUND trial ) The Breast 21 (2012)
29 Recurrence free survival Path negative Path positive p= Time to recurrence/death (months) path=neg path=pos There is no difference in adjuvant treatment decision making and recurrence free survival for patients with true negative and falsenegative AUS Tucker Ann Surg 2016
30 Thank You
EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY
EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY AXILLARY LYMPH NODE METASTASIS Axillary lymph node metastasis is one of the most
More informationEvaluation of the Axilla Post Z-0011 Trial New Paradigm
Evaluation of the Axilla Post Z-0011 Trial New Paradigm Belinda Curpen, MD, FRCPC; Tetyana Dushenkovska; Mia Skarpathiotakis MD, FRCPC; Carrie Betel, MD, FRCPC; Kalesha Hack, MD, FRCPC; Lara Richmond,
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationSurgical Considerations in Breast Cancer treated with Neoadjuvant Therapy
Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy Rebecca Warburton MD Department of Surgery, University of British Columbia Mount Saint Joseph Hospital, Providence Health Care
More informationTargeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center
Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic
More informationRecent Update in Surgery for the Management of Breast Cancer
Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National
More informationBreast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016
Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationIs Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?
Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationFeasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study
[ABS-0078] GBCC 2018 Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study Eun Young Kim 1, Kwan Ho Lee 1, Yong
More informationM D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
More informationSavitri Krishnamurthy, MD 1
EVOLVING TRENDS IN PATHOLOGIC EVALUATION OF AXILLARY LYMPH NODES IN BREAST CANCER Savitri Krishnamurthy, M.D. Professor Department of Pathology University of Texas M. D. Anderson Cancer Center AXILLARY
More informationPage 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.
AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In
More informationSurgical Issues in Neoadjuvant Chemotherapy
14 th Bossche Mamma Congress Ruwenbergstraat 7 5271 AG Sint Michielsgestel June 14, 2016 Surgical Issues in Neoadjuvant Chemotherapy Tari A. King MD FACS Chief, Breast Surgery Dana Farber/Brigham and Women
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationUpdates on management of the axilla in breast cancer the surgical point of view
Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationCURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?
CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!? I have no Disclosures Wolfgang Gatzemeier Breast Unit Milan, Italy 17th ESO-ESMO- EONS Masterclass in Clinical Oncology 24-29 MARCH 2018 Optimal
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationStudy on Efficacy of Preoperative Ultrasonography for Axillary Lymph Node Involvement In Breast Carcinoma
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861. Volume 13, Issue 4 Ver. II. (Apr. 2014), PP 01-05 Study on Efficacy of Preoperative Ultrasonography for Axillary
More informationSentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD
Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationPost-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both
More informationEvaluating the Z011 study and how local-regional therapy for early breast cancer may change
Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Karen Hoffman, M.D., M.H.Sc., M.P.H. Dept of Radiation Oncology The University of Texas MD Anderson Cancer Center
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationIndications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer
Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer Wendy A. Woodward, M.D. Ph.D. A sociate Profesor Section Chief, Breast Radiation Oncology
More informationSurgical Management of the Axilla
Surgical Management of the Axilla Jean-Francois Boileau, MD, MSc, FRCSC Surgical Oncologist, Montreal Jewish General Hospital Segal Cancer Centre Associate Member, Department of Oncology, McGill University
More informationSurgical Considera0ons with Neoadjuvant Treatment in Breast Cancer
Surgical Considera0ons with Neoadjuvant Treatment in Breast Cancer David R McCready MD MSc FRCSC FACS GaAuso Chair in Breast Surgical Oncology Professor of Surgery, University of Toronto Princess Margaret
More informationEvolution of Breast Surgery
Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,
More informationDonna Plecha, MD 1, Shiyu Bai, BS 2, Helen Patterson 3, Cheryl Thompson, PhD 4, and Robert Shenk, MD 5
Ann Surg Oncol DOI 10.1245/s10434-015-4527-y ORIGINAL ARTICLE BREAST ONCOLOGY Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven
More informationCan We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D.
Can We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D. I have no relevant financial relationship with commercial interests to disclose. More
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationPage 1. AD vs. no AD. Survival. Randomized Trials. All trials reported higher survival in the AD group. Years. Node-NegativeNegative
Sentinel Node Biopsy: The Past, The Present, and The Future Thomas B. Julian, M.D., F.A.C.S. Associate Professor of Human Oncology Drexel University College of Medicine Director of Breast Surgical Oncology
More informationEvaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy
Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy Eun Yoon Cho, MD, PhD Department of Pathology and Translational Genomics Samsung Medical Center Sungkyunkwan University
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationPractice of Axilla Surgery
Summer School of Breast Disease 2016 Practice of Axilla Surgery Axillary Lymph Node Dissection & Sentinel Lymph Node Biopsy 연세의대외과 박세호 Contents Anatomy of the axilla Axillary lymph node dissection (ALND)
More informationALND. Dr. MJ Vrancken
ALND Dr. MJ Vrancken ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice opera8on; dorsal approach 2 ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice
More informationSENTINEL LYMPH NODE BIOPSY FOR PATIENTS WITH EARLY-STAGE BREAST CANCER
SENTINEL LYMPH NODE BIOPSY FOR PATIENTS WITH EARLY-STAGE BREAST CANCER Clinical Practice Guideline Update Introduction The original ASCO evidence-based clinical practice guidelines on use of sentinel node
More informationManagement of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial
DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationUtility of Preoperative Ultrasound for Predicting pn2 or Higher Stage Axillary Lymph Node Involvement in Patients With Newly Diagnosed Breast Cancer
Women s Imaging Original Research Abe et al. Preoperative Ultrasound to Predict Axillary Lymph Node Involvement Women s Imaging Original Research Hiroyuki Abe 1 David Schacht Charlene A. Sennett Gillian
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationObjectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationEvaluation of the effect of neoadjuvant chemotherapy on tumor and axillary lymph nodes in locally advanced breast cancer: a study of 50 patients
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-0005-4 Evaluation of the effect of neoadjuvant chemotherapy on tumor and axillary lymph nodes in locally advanced breast cancer: a study of 50 patients
More informationReview Article Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients
BioMed Research International Volume 2015, Article ID 405949, 5 pages http://dx.doi.org/10.1155/2015/405949 Review Article Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients
More informationThe American Society of Breast Surgeons
The American Journal of Surgery (2008) 196, 477 482 The American Society of Breast Surgeons Scientific Presentation Award: The combination of axillary ultrasound and ultrasound-guided biopsy is an accurate
More informationWhat the surgeon wants from the radiologist before breast cancer surgery. Erica Patocskai Isabelle Trop
What the surgeon wants from the radiologist before breast cancer surgery Erica Patocskai Isabelle Trop Centre Hospitalier de l université de Montréal CAR, April 2013 Plan What is the role of MRI for breast
More informationLocally advanced BC: radiation therapy
Locally advanced BC: radiation therapy Philip Poortmans, MD, PhD 16 September 2016 Past-President Department of Radiation Oncology Conflict of interest: none Locally advanced breast cancer: radiation therapy
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationFine needle aspiration cytology guided by ultrasound of suspicious axillary lymph nodes in breast cancer patients
Hematology & Medical Oncology Research Article ISSN: 2398-8495 Fine needle aspiration cytology guided by ultrasound of suspicious axillary lymph nodes in breast cancer patients Waldeir de Almeida Júnior
More informationNCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham. Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence
NCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence 1 Interactive Workshop Session Professor Kieran Horgan Workshop
More informationWelcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:
More informationRecent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective
Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Tokyo-West Tokushukai Hospital Department of Breast Oncology Tokyo-West Tokushukai Hospital, Tokyo, Japan Kaz Sato, MD,
More informationJ.N., PRADHAN A.K., KUSTA M.K. ABSTRACT
Axillary Ultrasound Examination in the Selection of Carcinoma of Breast Patients for Sentinel Node Biopsy - A Prospective Study MISRA J.N., PRADHAN A.K., KUSTA M.K. ABSTRACT Background: Axillary lymph
More informationNEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE
NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE Dr. Joanne Chiu Medical Oncology Queen Mary Hospital The University of Hong Kong HONG KONG SURVEY FOR NEOADJUVANT THERAPY
More informationDiagnosis and staging of breast cancer and multidisciplinary team working
1 Diagnosis and staging of breast cancer and multidisciplinary team working Common symptoms and signs Over 90% of breast cancers (BCs) are local or regional when first detected. At least 60% of patients
More informationCONSENSUS ULTRASOUND SURVEILLANCE PROTOCOL AFTER POSITIVE SENTINEL LYMPH NODE BIOPSY FOR MELANOMA
CONSENSUS ULTRASOUND SURVEILLANCE PROTOCOL AFTER POSITIVE SENTINEL LYMPH NODE BIOPSY FOR MELANOMA Created by Drs P. Robins, Z. Al-Ogaili and B. Adler in collaboration with the WA Kirkbride Melanoma Advisory
More informationRelevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:
Axillary Node Recurrence N.L. Davis Associate Professor of Surgery, UBC Head of Surgical Oncology, BCCA Relevance In an attempt to minimize long term complications and to maximize cancer control, the management
More informationUpdate on the Surgical Management of Breast Cancer: What Happens After Imaging?
Update on the Surgical Management of Breast Cancer: What Happens After Imaging? Henry Kuerer, MD, PhD, FACS Department of Breast Surgical Oncology MD Anderson Cancer Center Outline Limiting and eliminating
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationTHE SURGEON S ROLE: THE AXILLA. Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital
THE SURGEON S ROLE: THE AXILLA Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital What are the concerns with treatment to the axilla Not necessary for
More informationOriginal Article. J Fac Med Baghdad 193. Introduction:
Original Article The value of Gray scale, color doppler and ultrasound guided- FNA in detection metastasis to the axillary lymph node in patient with primary breast cancer. * Qusay A. Fahad* Enam A.Al
More informationSentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy
The London Cancer Alliance West and South Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy Dimitri J Hadjiminas, MD, MPhil, FRCS (Consultant Breast & Endocrine Surgeon Imperial
More informationPreoperative Axillary Ultrasound in Breast Cancer: Safely Avoiding Frozen Section of Sentinel Lymph Nodes in Breast-Conserving Surgery
WESTERN SURGICAL ASSOCIATION ARTICLES Preoperative Axillary Ultrasound in Breast Cancer: Safely Avoiding Frozen Section of Sentinel Lymph Nodes in Breast-Conserving Surgery Irada Ibrahim-Zada, MD, PhD,
More informationThe Clinical Value of Axillary Ultrasonography for Detection of Axillary Lymph Node Metastasis in Cases with Breast Cancer
Original Article Middle East Journal of Cancer; October 2014; 5(4): 215-220 The Clinical Value of Axillary Ultrasonography for Detection of Axillary Lymph Node Metastasis in Cases with Breast Cancer Sedigheh
More informationMaria João Cardoso, MD, PhD
Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1 Conflict of Interest Disclosure No
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationEDITORIAL. Ann Surg Oncol (2011) 18: DOI /s
Ann Surg Oncol (2011) 18:2407 2412 DOI 10.1245/s10434-011-1593-7 EDITORIAL Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG)
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationPost Neoadjuvant therapy: issues in interpretation
Post Neoadjuvant therapy: issues in interpretation Disclosure: Overview D Prognostic features in assessment of post treatment specimens: Tumor size Cellularity Grade Receptors LN Neoadjuvant chemotherapy:
More informationBreast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina
Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast
More informationClinical Study Accuracy of Individual Descriptors and Grading of Nodal Involvement by Axillary Ultrasound in Patients of Breast Cancer
International Breast Cancer Volume 2013, Article ID 930596, 6 pages http://dx.doi.org/10.1155/2013/930596 Clinical Study Accuracy of Individual Descriptors and Grading of Nodal Involvement by Axillary
More information2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights Mylin A. Torres, M.D. Director, Glenn Family Breast Center Associate Professor Department of Radiation Oncology Winship Cancer Institute
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationPre- operative staging of the axilla
Pre- operative staging of the axilla Anthony J Maxwell University Hospital of South Manchester Outline Why stage the axilla? Optimising conventional US & needle sampling Other imaging and needle sampling
More informationBreast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland
Breast Cancer Screening and Treatment 2009 Mrs Belinda Scott Breast Surgeon Breast Associates Auckland BREAST CANCER THE PROBLEM 1.1 million women per year 410,000 deaths each year Increasing incidence
More informationFinancial Disclosure. Learning Objectives. None. To understand the clinical applicability of the NCDB Breast Cancer PUF
Preoperative Prediction of Node Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node Negative or Node Positive Breast Cancer Brittany L Murphy MD, Tanya Hoskin MS, Courtney
More informationUltrasound-guided fine needle aspiration cytology in staging clinically node-negative invasive breast cancer
Gynecol Surg (2012) 9:185 191 DOI 10.1007/s10397-011-0712-6 ORIGINAL ARTICLE Ultrasound-guided fine needle aspiration cytology in staging clinically node-negative invasive breast cancer Daniela Huber &
More informationAxillary Reverse Mapping to Reduce the Incidence of Lymphedema
Axillary Reverse Mapping to Reduce the Incidence of Lymphedema Nathalie Johnson,MD,FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Portland,Oregon Objectives for Learning Understand
More informationSpotlights on the surgery role at San Antonio
Spotlights on the surgery role at San Antonio Riccardo Masetti, MD Professor of Surgery Director, Multidisciplinary Breast Center Catholic University Rome, Italy Roma, 21 maggio 2017 Prof. Masetti has
More informationBreast Imaging. Jamie L. Wagner, DO, FACOS. Digital vs Analog Mammography (2-D) Surgical Oncologist. Patient with Cancer. Radiology/ Interventional
Breast Cancer Prevention, Treatment, and Survivorship Jamie L. Wagner, DO, FACOS Assistant Professor Chief, Division of Breast Surgery Department of Surgery Anesthesiology Surgical Oncologist Patient with
More information